Research Analysts Set Expectations for CLDX Q3 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a note issued to investors on Thursday, February 26th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will earn ($1.33) per share for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2026 earnings at ($1.38) EPS and FY2026 earnings at ($5.28) EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Barclays upped their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research note on Wednesday, December 17th. Stifel Nicolaus reiterated a “buy” rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, The Goldman Sachs Group raised their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $28.94 on Monday. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $31.31. The firm has a market cap of $1.93 billion, a PE ratio of -7.44 and a beta of 1.17. The company has a 50-day moving average of $25.80 and a two-hundred day moving average of $25.58.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.22). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CLDX. Aster Capital Management DIFC Ltd purchased a new stake in Celldex Therapeutics during the 3rd quarter worth about $26,000. Nisa Investment Advisors LLC grew its position in shares of Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 881 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics during the third quarter worth approximately $42,000. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Celldex Therapeutics in the third quarter valued at approximately $63,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.